(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.37%) $78.09
(0.27%) $2.21
(0.02%) $2 324.60
(0.09%) $27.57
(-0.10%) $987.40
(0.16%) $0.931
(0.42%) $10.94
(0.17%) $0.801
(-0.01%) $91.43
2.82% $ 5.83
@ $9.92
Wydano: 14 vas. 2024 @ 22:58
Zwrot: -41.23%
Poprzedni sygnał: vas. 13 - 20:33
Poprzedni sygnał:
Zwrot: 2.06 %
Live Chart Being Loaded With Signals
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments...
Stats | |
---|---|
Dzisiejszy wolumen | 317 195 |
Średni wolumen | 368 163 |
Kapitalizacja rynkowa | 254.80M |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $-0.0600 ) 2024-08-05 |
Last Dividend | $1.000 ( 2010-01-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.90 |
ATR14 | $0.00800 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-16 | Zaderej Karen L. | Buy | 84 847 | Common Stock |
2024-03-16 | Zaderej Karen L. | Buy | 12 975 | Common Stock |
2024-03-21 | Zaderej Karen L. | Sell | 3 166 | Common Stock |
2024-03-16 | Zaderej Karen L. | Buy | 12 500 | Common Stock |
2024-03-21 | Zaderej Karen L. | Sell | 3 086 | Common Stock |
INSIDER POWER |
---|
41.80 |
Last 98 transactions |
Buy: 1 200 055 | Sell: 468 598 |
Wolumen Korelacja
AxoGen Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
WRAP | 0.915 |
WDAY | 0.914 |
EA | 0.869 |
GTEC | 0.865 |
CVLG | 0.859 |
SFET | 0.857 |
CNET | 0.853 |
SMIT | 0.852 |
FATP | 0.848 |
AHPI | 0.848 |
10 Najbardziej negatywne korelacje | |
---|---|
SHYF | -0.915 |
RGLD | -0.91 |
UBFO | -0.902 |
MTRX | -0.899 |
ICUI | -0.897 |
TKNO | -0.893 |
IPKW | -0.892 |
STRA | -0.891 |
VRTS | -0.891 |
SGII | -0.889 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
AxoGen Inc Korelacja - Waluta/Towar
AxoGen Inc Finanse
Annual | 2023 |
Przychody: | $159.01M |
Zysk brutto: | $127.87M (80.42 %) |
EPS: | $-0.510 |
FY | 2023 |
Przychody: | $159.01M |
Zysk brutto: | $127.87M (80.42 %) |
EPS: | $-0.510 |
FY | 2022 |
Przychody: | $138.58M |
Zysk brutto: | $114.44M (82.58 %) |
EPS: | $-0.650 |
FY | 2021 |
Przychody: | $127.36M |
Zysk brutto: | $104.43M (81.99 %) |
EPS: | $-0.675 |
Financial Reports:
No articles found.
AxoGen Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0417 | 1992-07-10 |
Last Dividend | $1.000 | 2010-01-27 |
Next Dividend | $0 | N/A |
Payout Date | 2010-02-12 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $1.102 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.23 | -- |
Div. Sustainability Score | 0.965 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
1992 | $0.0417 | 0.45% |
1993 | $0 | 0.00% |
1994 | $0 | 0.00% |
1995 | $0 | 0.00% |
1996 | $0 | 0.00% |
1997 | $0 | 0.00% |
1998 | $0 | 0.00% |
1999 | $0 | 0.00% |
2000 | $0 | 0.00% |
2001 | $0 | 0.00% |
2002 | $0 | 0.00% |
2003 | $0 | 0.00% |
2004 | $0 | 0.00% |
2005 | $0.0600 | 4.00% |
2006 | $0 | 0.00% |
2007 | $0 | 0.00% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $1.000 | 24.10% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.130 | 1.500 | -2.60 | -3.90 | [0 - 0.5] |
returnOnAssetsTTM | -0.114 | 1.200 | -3.80 | -4.56 | [0 - 0.3] |
returnOnEquityTTM | -0.222 | 1.500 | -3.58 | -5.36 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.43 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.09 | 0.800 | 2.43 | 1.946 | [0.8 - 2.5] |
cashRatioTTM | 0.947 | 1.500 | 5.85 | 8.78 | [0.2 - 2] |
debtRatioTTM | 0.260 | -1.500 | 5.67 | -8.50 | [0 - 0.6] |
interestCoverageTTM | -34.79 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.244 | 2.00 | -0.0814 | -0.163 | [0 - 30] |
freeCashFlowPerShareTTM | -0.515 | 2.00 | -0.257 | -0.515 | [0 - 20] |
debtEquityRatioTTM | 0.520 | -1.500 | 7.92 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.797 | 1.000 | 0.0450 | 0.0450 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.114 | 1.000 | -4.28 | -4.28 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.218 | 1.000 | -2.32 | -2.32 | [0.2 - 2] |
assetTurnoverTTM | 0.878 | 0.800 | 7.48 | 5.99 | [0.5 - 2] |
Total Score | 0.965 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -11.52 | 1.000 | -1.265 | 0 | [1 - 100] |
returnOnEquityTTM | -0.222 | 2.50 | -2.30 | -5.36 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.515 | 2.00 | -0.172 | -0.515 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.244 | 2.00 | -0.0814 | -0.163 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.235 | 1.500 | -4.90 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.0645 | 1.000 | -4.11 | 0 | [0.1 - 0.5] |
Total Score | -1.898 |
AxoGen Inc
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej